Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. (NY: OGN )

20.59 +0.21 (+1.06%)
Streaming Delayed Price Updated: 2:01 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Organon & Co.

< Previous 1 2 3 Next >
Organon To Report First Quarter and Host Conference Call on May 4, 2023
From Organon & Co.
Via Business Wire
Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
From Organon & Co.
Via Business Wire
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022
From Organon
Via Business Wire
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
From Organon & Co.
Via Business Wire
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
From Organon & Co.
Via Business Wire
Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
From Organon & Co.
Via Business Wire
Organon To Present at the Piper Sandler 34th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
Organon Reports Results for the Third Quarter Ended September 30, 2022
From Organon & Co.
Via Business Wire
Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
From Organon & Co.
Via Business Wire
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
From Organon & Co.
Via Business Wire
Organon Reports Results for the Second Quarter Ended June 30, 2022
From Organon & Co.
Via Business Wire
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
From Organon & Co.
Via Business Wire
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
From Organon & Co.
Via Business Wire
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
From Organon & Co.
Via Business Wire
On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
From Organon & Co.
Via Business Wire
Organon Reports Results for the First Quarter Ended March 31, 2022
From Organon & Co.
Via Business Wire
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
From Organon & Co.
Via Business Wire
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
From Organon & Co.
Via Business Wire
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021
From Organon & Co.
Via Business Wire
Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam
From Organon & Co.
Via Business Wire
Organon antaa koko henkilökunnalleen vapaapäivän oman terveytensä edistämiseksi kansainvälisenä naisten päivänä
”Koska Covid-19-pandemialla on edelleen suhteettoman suuri vaikutus naisiin, Organon kutsuu muita organisaatioita liittymään joukkoonsa ja olemaan 
Via EIN Presswire
Organon Declares Paid Time Off for All Employees on International Women’s Day; Employees to Focus on Their Own Health in Recognition of Growing Women’s Health Inequity
From Organon & Co.
Via Business Wire
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022
From Organon & Co.
Via Business Wire
FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
From Organon & Co.
Via Business Wire
Organon To Present at the 40th Annual J.P. Morgan Healthcare Virtual Conference
From Organon & Co.
Via Business Wire
Organon Completes Acquisition of Forendo Pharma
From Organon & Co.
Via Business Wire
Organon To Present at the Evercore ISI 4th Annual HealthCONx Conference
From Organon & Co.
Via Business Wire
Organon Reports Results for the Third Quarter Ended September 30, 2021
From Organon & Co.
Via Business Wire
Organon to Acquire Forendo Pharma
From Organon & Co.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.